|
Continue the development of SWI to: a) make it more clinically viable by reducing phase processing artifacts; b) evaluate susceptibility itself by creating a susceptibility map of human tissue; c) study its role as a new MR angiographic method by simultaneously collecting MRA and SWI data; and d) speed up its acquisition time to less than 5 minutes for whole brain coverage, independent of any parallel imaging gain factor. ( 6/2009 - 5/2010 )
|